Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
Leuk Res. 2022 Dec;123:106970. doi: 10.1016/j.leukres.2022.106970. Epub 2022 Oct 22.
Two novel inhibitors of isocitrate dehydrogenase (IDHi), ivosidenib and enasidenib, significantly improve survival for AML patients with an IDH1 or IDH2 mutation, respectively; however, rash has been reported as a toxicity of IDHi. The objective of our study is to determine the incidence, grade, clinical, and histopathologic features of dermatologic adverse events (DAEs) secondary to IDHi. This study is a retrospective analysis of 169 patients who were treated with either ivosidenib or enasidenib as single agent or in combination with induction chemotherapy at Memorial Sloan Kettering Cancer Center from January 1, 2013 to April 1, 2021. DAEs thought to be possibly, probably, or definitely related to IDHi occurred in 55 of 169 patients [0.32, 95 % CI: 0.25 - 0.40]. Of a total 81 DAEs observed, the most common DAE types were inflammatory dermatoses (27 %); cutaneous vascular manifestations (8%); cutaneous infections (7%); and pruritus (2%). Notably, 50% of infections and 15.5% of rashes were high grade. Knowledge of these findings is critical to optimize the treatment and quality of life of patients with AML on IDHi.
两种新型异柠檬酸脱氢酶（IDH）抑制剂ivosidenib 和enasidenib 分别显著改善了 IDH1 或 IDH2 突变的 AML 患者的生存；然而，皮疹已被报道为 IDHi 的毒性。我们的研究目的是确定继发于 IDHi 的皮肤不良事件（DAE）的发生率、严重程度、临床和组织病理学特征。这项研究是对 2013 年 1 月 1 日至 2021 年 4 月 1 日期间在 Memorial Sloan Kettering 癌症中心接受ivosidenib 或 enasidenib 单药或联合诱导化疗治疗的 169 名患者的回顾性分析。认为可能、可能或肯定与 IDHi 相关的 DAE 发生在 169 名患者中的 55 名[0.32，95%CI：0.25-0.40]。在总共观察到的 81 个 DAE 中，最常见的 DAE 类型是炎症性皮肤病（27%）；皮肤血管表现（8%）；皮肤感染（7%）；和瘙痒（2%）。值得注意的是，50%的感染和 15.5%的皮疹为高级别。了解这些发现对于优化接受 IDHi 治疗的 AML 患者的治疗和生活质量至关重要。
